Polynucleotides Under Eyes: What to Expect and Realistic Results

Polynucleotides under the eyes involve injections intended to improve aspects of skin quality, such as fine lines and texture. Research reports promising short-term changes, but it does not establish a guaranteed result, a universal treatment course or a reliable correction for every dark circle, hollow or eye bag. Temporary swelling and bruising can also affect how the area looks after treatment.

The useful starting point is an assessment of what you want to change, followed by an explanation of the proposed product, risks and realistic limits. A recent systematic review of polynucleotides around the eyes describes its findings as preliminary.

Start with the concern beneath the treatment name

“Under-eye rejuvenation” can mean different things: finer skin texture, less visible lines, lighter-looking circles or a change in a hollow or bulge. Ask the practitioner which of these the proposed treatment actually aims to address.

Dark circles can involve several contributing factors. A 2026 observational study of periorbital hyperpigmentation reported improvement after a particular polynucleotide formulation, but its open-label design cannot establish that every type of darkness will respond or that the findings apply to every product.

Use an everyday description of your concern rather than trying to diagnose its cause yourself. For example: “The skin looks crinkled when I wear concealer” gives the practitioner a different starting question from “I want the hollow beneath my eye filled.” Improvement in a skin-quality measure is not proof that a structural concern will be corrected.

What the appointment can involve

The ACE Group World patient information leaflet describes assessment and consent, skin cleansing, possible local anaesthetic and administration using a needle or cannula. The method depends on the proposed treatment; this is an overview rather than Progen's individual protocol.

Before treatment, establish:

• The exact product and why it is appropriate for the eye area.
• Who will administer it and their relevant experience.
• Which injection method is proposed and what discomfort to expect.
• The common reactions, less common complications and available follow-up.
• The intended course, total cost and point at which progress will be reviewed.

Progen's polynucleotide treatment page lists PLINEST eye for periorbital skin texture. The manufacturer describes PLINEST Eye as a polynucleotide gel intended for intradermal use around the eyes. These descriptions do not confirm your suitability or which product will be offered at your appointment; ask the clinic to confirm.

What does the under-eye evidence actually measure?

Different study designs answer different questions. These findings are useful context, rather than a prediction of your result.

Evidence	What it tells us	What it cannot establish
A small randomised study involving 27 participants compared polynucleotides on one side with non-crosslinked hyaluronic acid on the other.	Some measured skin properties favoured polynucleotides, while overall aesthetic improvement scores did not differ significantly between groups.	That polynucleotides are universally better, or that this comparison proves correction of a deep tear trough.
A 2026 observational series followed 42 people receiving under-eye polynucleotide injections.	Patient-reported appearance and satisfaction improved compared with baseline.	How much improvement was caused by treatment compared with an untreated group, because there was no such comparator.

Sources: Lee and colleagues' randomised study and Ziade and colleagues' observational study.

The October 2026 eye-area systematic review included six studies, predominantly involving middle-aged women in Korean and Thai cohorts. It found short-term improvements but highlighted differing methods, limited follow-up and uncertainty about applying the results more widely. Evidence about crow's feet also should not automatically become a promise about every lower-eyelid concern. Read the review's findings and limitations.

Separate recovery from judging results

Swelling, discomfort and minor bruising were reported in the 42-person observational study. An early change in appearance therefore needs to be considered alongside the effects of the injections themselves. Under-eye study.

Ask your practitioner when the treated area should be reviewed and what would count as a meaningful improvement for your original concern. Agree how photographs will be compared, including similar lighting and expression, rather than relying on an immediate post-treatment image.

Request written guidance about makeup, skincare, exercise and any other restrictions. Your practitioner should confirm these timings for the actual product and procedure. A recovery calendar from another clinic cannot set your individual instructions.

Know how to obtain help afterwards

Before leaving, obtain the treating team's contact details and instructions for unexpected or worsening reactions. ACE Group World advises prompt practitioner review for unexpected side effects; severe pain or discolouration can require immediate medical attention. Patient information and complications guidance.

Do not wait for a routine cosmetic review if eye symptoms develop. NHS guidance advises urgent help for new blurred or double vision, and A&E or 999 if you suddenly cannot see or develop sudden severe eye pain. NHS advice on vision changes and emergencies.

Decide what would make treatment worthwhile for you

Before committing, ask: “What improvement is realistic for my particular concern, what might remain unchanged, and what happens if the benefit is limited?” Include the proposed course, aftercare and possible future treatment in the cost discussion.

The NHS recommends understanding the products, risks and full costs, and taking time to decide. Declining or postponing treatment remains an option.

If you are still comparing treatment categories, our polynucleotides and PRP facial comparison addresses that broader question. For clinic information and consultation options in Bournemouth, explore polynucleotide treatment at Progen.

Frequently asked questions

Will I need the same number of sessions used in a study?

Not necessarily. A research schedule describes that study's product and participants. Ask your practitioner to confirm the proposed course and review points for your assessment; do not use a published study as your personal treatment schedule.

Does a study comparing polynucleotides with hyaluronic acid prove they replace tear-trough filler?

No. The small randomised study discussed here used non-crosslinked hyaluronic acid as its comparator and measured several skin and aesthetic outcomes. It does not establish that every polynucleotide product can replace treatment intended for structural volume correction.

What should I say if I have already had treatment around my eyes?

Tell the practitioner which procedures and products you have had, approximately when, and whether you experienced any problems. Ask whether that history changes the assessment or proposed plan rather than assuming treatments can be combined.

Explore polynucleotide treatment at Progen

Sources and further information

• Accessed 4 November 2026. Manufacturer identifies PLINEST Eye as a polynucleotide gel for intradermal use in the periocular area.
• Accessed 4 November 2026. Supports assessment, consent, cleansing, possible anaesthetic, needle/cannula administration and prompt review of unexpected reactions, including urgent concern about severe pain or discolouration.
• Accessed 4 November 2026. Lee et al., online 2020 and 2022 journal issue: 27-person randomised split-face comparison with non-crosslinked hyaluronic acid; some skin measures favoured PN, but overall aesthetic improvement scores were not significantly different.
• Accessed 4 November 2026. Ziade et al., February 2026: observational series of 42 patients reported improved appearance and satisfaction after under-eye injections. Associated full-text results describe swelling, discomfort and minor bruising.
• Accessed 4 November 2026. Ahuja et al., published 10 October 2026: six periorbital studies reported short-term improvements, with heterogeneous methods, restricted populations and limited follow-up; authors regard findings as preliminary.
• Accessed 4 November 2026. Amado et al., 15 May 2026: open-label observational research reported improvement in periorbital hyperpigmentation after a specified PN-HPT formulation.
• Accessed 4 November 2026; page reviewed 28 August 2025. New blurred/double vision warrants urgent help; sudden inability to see or sudden severe eye pain requires A&E or 999.
• Accessed 4 November 2026; page reviewed 22 May 2023. Supports discussing products, risks, practitioner experience, full costs and taking time before deciding.
• Accessed 4 November 2026. Existing treatment route lists PLINEST eye for periorbital texture and provides consultation options.